Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.71
PLX's Cash-to-Debt is ranked lower than
80% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. PLX: 0.71 )
Ranked among companies with meaningful Cash-to-Debt only.
PLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.51  Med: No Debt Max: No Debt
Current: 0.71
Equity-to-Asset -0.21
PLX's Equity-to-Asset is ranked lower than
94% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. PLX: -0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
PLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.1 Max: 0.8
Current: -0.21
-1.15
0.8
Piotroski F-Score: 6
Altman Z-Score: -3.73
Beneish M-Score: 7.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -451.57
PLX's Operating Margin % is ranked lower than
73% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. PLX: -451.57 )
Ranked among companies with meaningful Operating Margin % only.
PLX' s Operating Margin % Range Over the Past 10 Years
Min: -8239.43  Med: -676.52 Max: -35.36
Current: -451.57
-8239.43
-35.36
Net Margin % 648.48
PLX's Net Margin % is ranked higher than
99% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. PLX: 648.48 )
Ranked among companies with meaningful Net Margin % only.
PLX' s Net Margin % Range Over the Past 10 Years
Min: -8103.09  Med: -643.26 Max: 1329.9
Current: 648.48
-8103.09
1329.9
ROA % 58.67
PLX's ROA % is ranked higher than
98% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. PLX: 58.67 )
Ranked among companies with meaningful ROA % only.
PLX' s ROA % Range Over the Past 10 Years
Min: -67.46  Med: -36.59 Max: 66.1
Current: 58.67
-67.46
66.1
ROC (Joel Greenblatt) % -317.89
PLX's ROC (Joel Greenblatt) % is ranked lower than
54% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. PLX: -317.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -988.83  Med: -225.65 Max: -67
Current: -317.89
-988.83
-67
3-Year Revenue Growth Rate -50.50
PLX's 3-Year Revenue Growth Rate is ranked lower than
84% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PLX: -50.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 323.2
Current: -50.5
0
323.2
3-Year EBITDA Growth Rate 36.90
PLX's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. PLX: 36.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.3  Med: -11.2 Max: 83
Current: 36.9
-53.3
83
3-Year EPS without NRI Growth Rate 30.70
PLX's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. PLX: 30.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -5.8 Max: 54.6
Current: 30.7
-49.3
54.6
GuruFocus has detected 4 Warning Signs with Protalix BioTherapeutics Inc $PLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PLX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PLX Guru Trades in Q1 2016

Jim Simons 54,900 sh (+162.27%)
» More
Q2 2016

PLX Guru Trades in Q2 2016

Jim Simons 102,900 sh (+87.43%)
» More
Q3 2016

PLX Guru Trades in Q3 2016

Jim Simons 180,900 sh (+75.80%)
» More
Q4 2016

PLX Guru Trades in Q4 2016

Jim Simons 479,300 sh (+164.95%)
» More
» Details

Insider Trades

Latest Guru Trades with PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:NVIV, NAS:MRTX, NAS:EVGN, OTCPK:BCDA, OTCPK:PHGUF, OTCPK:PAIOF, NAS:PPHM, NAS:ABUS, NAS:GNCA, NAS:MDWD, NAS:ATHX, NAS:AQB, NAS:ALBO, NAS:DVAX, NAS:CTIC, NAS:VVUS, OTCPK:DGJI, OTCPK:BNOEF, NAS:CXRX, NAS:ARWR » details
Traded in other countries:PBD.Germany, PLX.Israel,
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc was originally incorporated in the State of Florida in April 1992. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx. Using its ProCellEx system, it is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Its initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The Company has developed ElelysoTM, its first drug product, ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The Company is now also applying the properties of its ProCellEx system for the oral delivery of therapeutic proteins. The Company relies on a single approved supplier for certain materials relating to the current expression of its proprietary biotherapeutic proteins through ProCellEx. It faces competition from companies with approved treatments of Gaucher disease. Some such companies include iBio, Inc., Medicago Inc., and Greenovation Biotech GmbH. The Company has 94 pending patent applications and one joint pending patent application with a third party. The Company is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.

Ratios

vs
industry
vs
history
PE Ratio 2.16
PLX's PE Ratio is ranked higher than
93% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. PLX: 2.16 )
Ranked among companies with meaningful PE Ratio only.
PLX' s PE Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.29 Max: 2.24
Current: 2.16
0.6
2.24
Price-to-Owner-Earnings 3.16
PLX's Price-to-Owner-Earnings is ranked higher than
91% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. PLX: 3.16 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PLX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.88  Med: 2.32 Max: 33.92
Current: 3.16
0.88
33.92
PS Ratio 15.00
PLX's PS Ratio is ranked lower than
63% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. PLX: 15.00 )
Ranked among companies with meaningful PS Ratio only.
PLX' s PS Ratio Range Over the Past 10 Years
Min: 4.17  Med: 44.82 Max: 1618
Current: 15
4.17
1618
Current Ratio 5.77
PLX's Current Ratio is ranked higher than
69% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. PLX: 5.77 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 5.77 Max: 72.77
Current: 5.77
1.02
72.77
Quick Ratio 5.30
PLX's Quick Ratio is ranked higher than
67% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. PLX: 5.30 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.3 Max: 72.77
Current: 5.3
0.96
72.77
Days Inventory 325.82
PLX's Days Inventory is ranked lower than
87% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. PLX: 325.82 )
Ranked among companies with meaningful Days Inventory only.
PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 175.68 Max: 3304.7
Current: 325.82
24.15
3304.7
Days Sales Outstanding 107.48
PLX's Days Sales Outstanding is ranked lower than
75% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PLX: 107.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 338.48 Max: 2016.91
Current: 107.48
14.95
2016.91
Days Payable 225.87
PLX's Days Payable is ranked higher than
87% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. PLX: 225.87 )
Ranked among companies with meaningful Days Payable only.
PLX' s Days Payable Range Over the Past 10 Years
Min: 225.87  Med: 967.86 Max: 2222.44
Current: 225.87
225.87
2222.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.20
PLX's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. PLX: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -2.2
-539.3
14

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.33
PLX's Price-to-Median-PS-Value is ranked higher than
86% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. PLX: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.8 Max: 30.09
Current: 0.33
0.01
30.09
Earnings Yield (Greenblatt) % -20.34
PLX's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. PLX: -20.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -88.08  Med: 5037.85 Max: 12682.8
Current: -20.34
-88.08
12682.8

More Statistics

Revenue (TTM) (Mil) $7.12
EPS (TTM) $ 0.50
Beta0.79
Short Percentage of Float2.20%
52-Week Range $0.26 - 1.48
Shares Outstanding (Mil)123.78

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 11 16 18
EPS ($) -0.40 -0.33 -0.25
EPS without NRI ($) -0.40 -0.33 -0.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PLX

Headlines

Articles On GuruFocus.com
Avago Technologies' Memory, FBAR, and Connectivity Business Will Take It Higher Oct 23 2014 
Weekly CFO Sells Highlight: AXP, CRAY, PLX, KMB, ITW, CATM, CAR May 07 2012 
Protalix BioTherapeutics Inc Reports Operating Results (10-K) Feb 23 2011 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Nov 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Oct 08 2010 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 70,000 Shares Sep 08 2010 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 05 2010 
Protalix BioTherapeutics Inc (PLX) CEO and President David Aviezer sells 244,238 Shares Oct 21 2009 
Protalix BioTherapeutics Inc (PLX) VP, CFO Yossi Maimon sells 150,000 Shares Oct 19 2009 
Protalix BioTherapeutics Inc Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta Feb 17 2017
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure Feb 16 2017
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations Feb 14 2017
Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders Feb 14 2017
Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 Feb 13 2017
M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and... Feb 03 2017
Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7% Jan 30 2017
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017 Jan 09 2017
Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of... Jan 04 2017
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to... Jan 04 2017
Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million... Jan 04 2017
Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial... Jan 04 2017
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Jan 03 2017
Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of... Jan 03 2017
Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data Dec 30 2016
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events Dec 27 2016
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to... Dec 27 2016
Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund Dec 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)